Physiomics plc (AIM: PYC), a provider of technology-based solutions to predict the effects of cancer treatment regimens for the biopharma industry, is pleased to confirm that based on its current unaudited accounts at 20th June, it is trading ahead of market expectations for its full financial year ending 30th June 2018.
The Company’s anticipated total income for the full year is likely to be greater than £495k and its anticipated loss will be materially reduced compared to current market expectations.
Dr Jim Millen, CEO said: “We are pleased that as a result of the hard work of the team, the Company continues to show progress not only in attracting new clients but in translating this into bookable revenue which is moving us closer to profitability”.
Dr Jim Millen, CEO
+44 (0)1865 784 980
WH Ireland Limited (Nomad)
+44 (0) 161 832 2174
Hybridan LLP (Broker)
Claire Louise Noyce
+44 (0) 203 764 2341
This announcement is released by Physiomics plc and contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014 (MAR), and is disclosed in accordance with the Company's obligations under Article 17 of MAR.
Notes to Editor
Physiomics plc (AIM: PYC) is a solutions provider to the R&D based pharmaceutical and biotechnology industry with a focus on oncology. The Company’s Virtual Tumour technology uses computer modelling to predict the effects of cancer drugs and treatments to improve the success rate of drug discovery and development projects while reducing time and cost. The predictive capability of Virtual Tumour has been confirmed by 55 projects, involving over 25 targets and 60 drugs, and has worked with clients such as Merck KGaA, Merck & Co, Bayer and Lilly.
Based in Oxford UK, the Company works with clients worldwide to support their pre-clinical and clinical oncology development programs. Its team of scientists and computer modelling experts provide bespoke solutions encompassing data, analytics and insight.
Physiomics senior management has academic and commercial expertise, including over 90 years collectively of working in oncology and/or computational biology and over 100 publications in peer reviewed journals.
For more information please visit: